Document:

​

Exhibit 4.5
DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO
SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934
As of March 31, 2021, the end of the period covered by this Quarterly Report on Form 10-Q, the Company has three classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): the Company’s common stock, $0.0001 par value (“common stock”), rights to purchase common stock (“rights”), and units comprised of one share of common stock and one right.
The following description of the Company’s capital stock and provisions of the Company’s amended and restated certificate of incorporation, bylaws and the Delaware General Corporation Law are summaries and are qualified in their entirety by reference to the Company’s amended and restated certificate of incorporation and bylaws and the text of the Delaware General Corporation Law. Copies of these documents have been filed with the SEC as exhibits to the Quarter Report on Form 10-Q to which this description has been filed as an exhibit.
The Company’s authorized capital stock consists of 30,000,000 shares of common stock, par value $0.0001 per share. The authorized and unissued shares of common stock are available for issuance without further action by the Company’s stockholders, unless such action is required by applicable law or the rules of any stock exchange on which the Company’s securities may be listed. Unless approval of stockholders is so required, the Company’s board of directors will not seek stockholder approval for the issuance and sale of common stock.
Units
Each unit consists of one share of common stock, $0.0001 par value and one right to acquire 1/10 of one share of common stock upon the consummation of an initial business combination. In the event the Company will not be the surviving company upon completion of its initial business combination, each holder of a right will be required to affirmatively convert his, her or its rights in order to receive the one- tenth (1/10) of a share underlying each right upon consummation of the business combination. The Company will not issue fractional shares in connection with an exchange of rights. Fractional shares will either be rounded down to the nearest whole share or otherwise addressed in accordance with the applicable provisions of the Delaware General Corporation Law. As a result, shareholders must hold rights in multiples of 10 in order to receive shares for all of his, her, or its rights upon closing of a business combination. The private units held by the Company’s sponsor and underwriters are identical to the public units described above.
Common Stock
Holders of record of the Company’s common stock are entitled to one vote for each share held on all matters to be voted on by stockholders. In connection with any vote held to approve the Company’s initial business combination, the Company’s insiders, officers and directors, have agreed to vote their respective shares of common stock owned by them in favor of the proposed business combination.
The Company will consummate its initial business combination only if public stockholders do not exercise conversion rights in an amount that would cause its net tangible assets to be less than $5,000,001 and a majority of the outstanding shares of common stock voted are voted in favor of the business combination.
The Company’s board of directors is divided into three classes, each of which will generally serve for a term of three years with only one class of directors being elected in each year. There is no cumulative voting with respect to the election of directors, with the result that the holders of more than 50% of the shares eligible to vote for the election of directors can elect all of the directors.
Pursuant to the Company’s amended and restated certificate of incorporation, if the Company does not consummate its initial business combination within 9 months of its initial public offering (the “IPO”) (or 15 months from the closing of its IPO if the Company has executed a definitive agreement for an initial business combination within 9 months from the closing of its IPO but have not completed the initial business combination within such 9-month period), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible
​
​

​

​

but not more than ten business days thereafter, redeem 100% of the outstanding public shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and its board of directors, dissolve and liquidate, subject (in the case of (ii) and (iii) above) to its obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. The Company’s insiders have agreed to waive their rights to share in any distribution with respect to their insider shares and private shares. However, if the Company anticipates that it may not be able to consummate its initial business combination within 9 months from the closing of its IPO and it has not entered into a definitive agreement for an initial business combination by such date, the Company’s insiders or their affiliates may, but are not obligated to, extend the period of time to consummate a business combination two times by an additional three months each time (for a total of up to 15 months to complete a business combination), provided that, pursuant to the terms of its amended and restated certificate of incorporation and the trust agreement entered between the Company and Continental Stock Transfer & Trust Company on January 7, 2021, the only way to extend the time available for the Company to consummate its initial business combination in the absence of a definitive agreement is for the Company’s insiders or their affiliates or designees, upon five days’ advance notice prior to the applicable deadline, to deposit into the trust account $575,000 ($0.10 per share, or an aggregate of $1,150,000), on or prior to the date of the applicable deadline. In the event that they elected to extend the time to complete a business combination and deposited the applicable amount of money into trust, the insiders would receive a non-interest bearing, unsecured promissory note equal to the amount of any such deposit that will not be repaid in the event that the Company is unable to close a business combination unless there are funds available outside the trust account to do so. Such notes would either be paid upon consummation of the Company’s initial business combination, or, at the relevant insider’s discretion, converted upon consummation of its business combination into additional private units at a price of $10.00 per unit. The Company’s shareholders have approved the issuance of the private units upon conversion of such notes, to the extent the holder wishes to so convert such notes at the time of the consummation of its initial business combination. In the event that the Company receives notice from its insiders five days prior to the applicable deadline of their intent to effect an extension, the Company intends to issue a press release announcing such intention at least three days prior to the applicable deadline. In addition, the Company intends to issue a press release the day after the applicable deadline announcing whether or not the funds had been timely deposited. The Company’s insiders and their affiliates or designees are not obligated to fund the trust account to extend the time for the Company to complete its initial business combination. To the extent that some, but not all, of the Company’s insiders, decide to extend the period of time to consummate the Company’s initial business combination, such insiders (or their affiliates or designees) may deposit the entire amount required.
The Company’s stockholders have no conversion, preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable to the shares of common stock, except that public stockholders have the right to sell their shares to the Company in any tender offer or have their shares of common stock converted to cash equal to their pro rata share of the trust account if they vote on the proposed business combination and the business combination is completed. If the Company hold a stockholder vote to amend any provisions of the Company’s certificate of incorporation relating to stockholder’s rights or pre-business combination activity (including the substance or timing within which the Company has to complete a business combination), the Company will provide its public stockholders with the opportunity to redeem their shares of common stock upon approval of any such amendment at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account and not previously released to the Company to pay its franchise and income taxes, divided by the number of then outstanding public shares, in connection with any such vote. In either of such events, converting stockholders would be paid their pro rata portion of the trust account promptly following consummation of the business combination or the approval of the amendment to the certificate of incorporation. If the business combination is not consummated or the amendment is not approved, stockholders will not be paid such amounts.
​

2

​

Rights included as part of units
Except in cases where the Company is not the surviving company in a business combination, each holder of a right will automatically receive one- tenth (1/10) of a share of common stock upon consummation of the Company’s initial business combination, even if the holder of a public right converted all shares of common stock held by him, her or it in connection with the initial business combination or an amendment to the Company’s certificate of incorporation with respect to the Company’s pre-business combination activities. In the event the Company will not be the surviving company upon completion of its initial business combination, each holder of a right will be required to affirmatively convert his, her or its rights in order to receive the one- tenth (1/10) of a share underlying each right upon consummation of the business combination. No additional consideration will be required to be paid by a holder of rights in order to receive his, her or its additional shares of common stock upon consummation of an initial business combination. The shares issuable upon exchange of the rights will be freely tradable (except to the extent held by affiliates of the Company). If the Company enter into a definitive agreement for a business combination in which it will not be the surviving entity, the definitive agreement will provide for the holders of rights to receive the same per share consideration the holders of the common stock will receive in the transaction on an as-converted into common stock basis.
The Company will not issue fractional shares in connection with an exchange of rights. Fractional shares will either be rounded down to the nearest whole share or otherwise addressed in accordance with the applicable provisions of the Delaware General Corporation Law. As a result, holders must hold rights in multiples of 10 in order to receive shares for all of the holders’ rights upon closing of a business combination. If the Company is unable to complete an initial business combination within the required time period and it liquidate the funds held in the trust account, holders of rights will not receive any of such funds with respect to their rights, nor will they receive any distribution from the Company’s assets held outside of the trust account with respect to such rights, and the rights will expire worthless. Further, there are no contractual penalties for failure to deliver securities to the holders of the rights upon consummation of an initial business combination. Additionally, in no event will the Company be required to net cash settle the rights. Accordingly, the rights may expire worthless.
Certain Anti-Takeover Effects of Delaware Law and Provisions of the Company’s Amended and Restated Certificate of Incorporation and Bylaws
The Company is subject to the provisions of Section 203 of the DGCL regulating corporate takeovers. This statute prevents certain Delaware corporations, under certain circumstances, from engaging in a “business combination” with:
​
		•
	a stockholder who owns 10% or more of our outstanding voting stock (otherwise known as an “interested stockholder”);

​
		•
	an affiliate of an interested stockholder; or

​
		•
	an associate of an interested stockholder, for three years following the date that the stockholder became an interested stockholder.

​
A “business combination” includes a merger or sale of more than 10% of the Company’s assets. However, the above provisions of Section 203 do not apply if:
​
		•
	the board of directors approves the transaction that made the stockholder an “interested stockholder,” prior to the date of the transaction;

​
		•
	after the completion of the transaction that resulted in the stockholder becoming an interested stockholder, that stockholder owned at least 85% of our voting stock outstanding at the time the transaction commenced, other than statutorily excluded shares of common stock; or

​
		•
	on or subsequent to the date of the transaction, the business combination is approved by the board of directors and authorized at a meeting of stockholders, and not by written consent, by an affirmative vote of at least two-thirds of the outstanding voting stock not owned by the interested stockholder.

​

3

​

Exclusive Forum For Certain Lawsuits
The Company’s amended and restated certificate of incorporation requires that derivative actions brought in the Company’s name, actions against directors, officers and employees for breach of fiduciary duty and other similar actions not including claims that arise under the Securities Act or Exchange Act, may be brought only in the Court of Chancery in the State of Delaware. This provision may have the effect of discouraging lawsuits against the Company’s directors and officers.
Special meeting of stockholders
The Company’s bylaws provide that special meetings of stockholders may be called by resolution of the board of directors, or by the Chairman or the President.
Advance notice requirements for stockholder proposals and director nominations
The Company’s bylaws provide that written or printed notice of a stockholder meeting stating the place, day and hour of the meeting and, in case of a special meeting, stating the purpose or purposes for which the meeting is called, and in case of a meeting held by remote communication stating such means, will need to be delivered to the Company’s Chairman or the President, the Secretary, or the persons calling the meeting, not later than the close of business not less than 10 nor more than 60 days before the date of the meeting of stockholders. These provisions may preclude our stockholders from bringing matters before an annual meeting of stockholders or from making nominations for directors at an annual meeting of stockholders.
Authorized but unissued shares
The Company’s authorized but unissued common stock is available for future issuances without stockholder approval and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock could render more difficult or discourage an attempt to obtain control of the Company by means of a proxy contest, tender offer, merger or otherwise.

4EX-10.8

 Exhibit 10.8 
  

			
	

	  	 575 Florida St. Suite# 150

San Francisco, CA 94110, United States

+1-415-356-3400 |
spire.com

 May 24, 2019 
 Peter
Platzer 
 Dear Peter, 
 Spire Global, Inc.
(the “Company”) is pleased to continue your employment with the Company on the terms set forth herein in this letter (“Agreement”). This Agreement memorializes the terms of your ongoing relationship with the Company and
supersedes any other employment offer letter between you and the Company, except for the Foreign Assignment Letter signed by you on December 12, 2017 and is attached hereto as Exhibit A (the “Foreign Assignment Letter”). 

1. Position. Your title will be Chief Executive Officer and you will report to the Company’s Board of Directors (the
“Board”). This is a full-time position. While you render services to the Company, you will not engage in any other employment, consulting or other business activity (whether full-time or part-time) that could create a conflict of interest
with the Company. As the Chief Executive Officer, you shall also continue to serve as chairman of the Board for no additional compensation. By signing this Agreement, you confirm to the Company that you have no contractual commitments or other legal
obligations that would prohibit you from performing your duties for the Company. 
 2. Compensation. 

(a) Cash Compensation. The Company will pay you a base salary at the rate of $300,000.00 per year (the “Base Salary”),
payable in accordance with the Company’s standard payroll schedule and subject to applicable deductions and withholdings. This salary will be subject to periodic review and adjustments at the Company’s discretion. 

(b) Annual Option Grant. In addition to your Base Salary, after the twelve (12) month anniversary of the date of this Agreement, you will
be eligible to receive annual stock option grants (the “Annual Stock Option Grants”) issued pursuant to the terms of the Company’s equity compensation plans. Such Annual Stock Option Grants will be in relative proportion to “Top
Off” grants made to other employees of the Company, adjusted accordingly for your rank and seniority. The actual amount and terms of any such grants will be determined by the Board (or a committee thereof), in its sole discretion. The Annual
Stock Option Grants will be subject to the terms and conditions applicable to options granted under the Company’s 2012 Stock Option and Grant Plan (the “Plan”), as described in the Plan and the applicable stock option agreement. 

3. Employee Benefits. As a regular employee of the Company, you will be eligible to participate in a number of Company-sponsored
benefits plans currently and hereafter maintained by the Company of general applicability to other similarly-situated employees of the Company, subject to the eligibility requirements of such plans. 

  
 1 

			
	 

  
  
	  	 575 Florida St. Suite# 150

San Francisco, CA 94110, United States

+1-415-356-3400 | spire.com

  

 4. Proprietary Information and Inventions Agreement. You are required to abide by the
Proprietary Information and Inventions Agreement that you previously signed with the Company on September 30, 2012. However, as a condition of your continued employment with the Company, you agree to sign the enclosed Proprietary Information
and Inventions Agreement that is attached as Exhibit B. 
 5. Employment Relationship. The parties
agree that your employment with the Company shall be on an at-will basis at all times. Either the Company or you may terminate this Agreement and the employment relationship for any reason or no reason at all,
and with or without cause. However, if your employment relationship is terminated by the Company without Cause, or by you for Good Reason (both as defined below), the Company shall pay you as severance as commencing on the date that the business
relationship is severed, consisting of: (i) nine months of your then-current Base Salary payable in accordance with the Company’s standard payroll schedule for the nine month period following such severance date (subject to applicable
deductions and withholdings), (ii) nine months of COBRA premiums (based on your level of coverage for you and your dependents (if applicable)), in the event you elect such COBRA coverage (such payments to cease if you obtain alternative health
insurance coverage), (iii) all of your outstanding equity awards will accelerate and immediately become fully vested, and (iv) the period to exercise any award will become the Expiration Date of such award. The foregoing payments are subject to
you having delivered to the Company an executed copy of a release of claims in form and substance acceptable to the Company, and such release having become effective and irrevocable as of the date of execution. The Company may, in its sole
discretion, elect to relieve you of some or all of your duties during all or some of this period and to disable your access to the Company’s facilities, systems, and equipment. If the Company terminates the employment relationship with Cause,
the Company may terminate the employment relationship immediately and without notice and may terminate the Foreign Assignment Letter (at which point no further amounts or benefits shall be due thereunder). Except as otherwise provided in this
Section, nothing in this Agreement or in any oral or written statement shall limit the at-will basis of the parties’ employment relationship or limit either party’s right to terminate the employment at-will. The parties further agree that this provision and the at-will nature of the employment relationship between the Company and you may only be modified, changed, or
amended in a writing signed by the Company’s General Counsel expressly stating that your at-will employment relationship is changed. For purposes of this Agreement, “Cause” shall mean:
(i) an unauthorized use or disclosure by you of the Company’s confidential information or trade secrets, which use or disclosure causes material harm to the Company; (ii) a material failure by you to comply with the Company’s
written policies or rules after receiving written notification of such failure and if curable, provision of a reasonable cure period of no less than 30 days following the receipt of such notice; (iii) your conviction of, or plea of
“guilty” or “no contest” to, a felony, or your commission of any act of moral turpitude, dishonesty or fraud against, or the misappropriation of material property belong to, the Company or its affiliates; (iv) your gross
misconduct which results in material harm to the Company; (v) a continuing failure by you to perform your reasonably assigned duties after receiving written notification of such failure and provision of a reasonable cure period of no less than
30 days following the receipt of such notice; or (vi) a failure by you to cooperate in good faith with a governmental or internal investigation of the Company or its directors, officers or employees, if the Company has requested your
cooperation. “Good Reason” shall mean: (i) a material reduction of your duties, position or responsibilities; provided, however, that a reduction in duties, position or 

  
 2 

			
	 

  
  
	  	 575 Florida St. Suite# 150

San Francisco, CA 94110, United States

+1-415-356-3400 | spire.com

  

 
responsibilities solely by virtue of the Company being acquired and made part of a larger entity will not constitute “Good Reason”; (ii) a material reduction in your Base Salary (except
where there is a reduction applicable to the management team generally); provided, however, that a temporary reduction in your Base Salary of ten percent (10%) or less in any one year will not be deemed a material reduction; or (iii) a material
change in the geographic location of your primary work facility or location; provided, that a relocation of less than fifty (25) miles from your current location will not be considered a material change in geographic location; and, provided,
further that a relocation in accordance with the terms of the Foreign Assignment Letter (including, without limitation, your relocation at the end of the term thereof) shall not be consideration a material change in geographic location. Your
resignation will not be deemed to be for Good Reason unless you have first provided the Company with written notice of the acts or omissions constituting the grounds for “Good Reason” within ninety (90) days of the initial existence
of the grounds for “Good Reason” and a reasonable cure period of not less than thirty (30) days following the date the Company receives such notice, and such condition has not been cured during such period. 

6. Tax Matters. 
 (a)
Withholding. All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law. 

(b) Tax Advice. You are encouraged to obtain your own tax advice regarding your compensation from the Company. You agree that the
Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or the Board related to tax liabilities arising from your compensation. 

(c) Section 409A. The Company intends that the payments and benefits herein shall be exempt from Section 409A of the Internal
Revenue Code of 1986, as amended (“Section 409A”) and this letter agreement shall be construed for all purposes in a manner consistent with such intent. To the extent any payments or benefits provided herein are determined to be
subject to Section 409A, such payments or benefits will be made in a manner that complies with Section 409A, including any necessary delays in payment. For purposes of this letter, your termination date means the date on which you
experience a “Separation from Service” within the meaning of Section 1.409A-1(h) of the Treasury Regulations. 

(d) Section 280G. If upon a Sale Event, the Company determines that you are a “disqualified individual” as defined under
Section 280G of the Internal Revenue Code of 1986, as amended (“Section 280G”), we will require full disclosure of all payments and benefits under this letter agreement to the Company’s stockholders, who must also be asked
to approve all “parachute payments” as defined under Section 280G. Should the Company’s stockholders not approve these payments and benefits in accordance with Section 280G, then such payments and benefits will be reduced to
the extent necessary so that such retention incentives do not constitute “parachute payments” under Section 280G. 

  
 3 

			
	 

  
  
	  	 575 Florida St. Suite# 150

San Francisco, CA 94110, United States

+1-415-356-3400 | spire.com

  

 7. Interpretation, Amendment and Enforcement. Except for any arbitration agreement
that you may enter into or may have entered into in connection with your employment, this Agreement, and Exhibits A-B constitute the complete agreement between you and the Company, contain all of the
terms of your employment with the Company and supersede any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. By signing below, the parties agree and acknowledge that you will not
receive duplicative compensation and/or benefits under this Agreement and the Foreign Assignment Letter. This Agreement and the Foreign Assignment Letter provide for one unified set of terms during the period of time you are on foreign assignment
pursuant to the Foreign Assignment Letter. For example, during the period of time that you are on foreign assignment pursuant to the Foreign Assignment Letter, you will receive only your Base Salary and not separate salary payments under both
contracts. This Agreement may not be amended or modified, except by an express written agreement signed by both you and a duly authorized officer of the Company. The terms of this Agreement and the resolution of any disputes as to the meaning,
effect, performance or validity of this Agreement or arising out of, related to, or in any way connected with, this letter agreement, your employment with the Company or any other relationship between you and the Company (the “Disputes”)
will be governed by California law, excluding laws relating to conflicts or choice of law. Unless you have entered into or subsequently enter into any arbitration agreement in connection with your employment, you and the Company submit to the
exclusive personal jurisdiction of the federal and state courts located in San Francisco County, California, in connection with any Dispute or any claim related to any Dispute. 

9. Execution. This letter agreement may be executed in counterparts, each of which will be considered an original, but all of which
together will constitute one agreement. If a party signs the signature page and faxes (or scans and emails) the signature page to the other party or signs this letter agreement by electronic signature, then such signature page shall be deemed an
original signature page to this letter agreement and shall constitute the execution and delivery of this letter agreement by the sending party. 

10. Miscellaneous. To the extent required pursuant to the acceleration of vesting provisions contained in Sections 4 and 6 of this
Agreement, all of your outstanding equity grants will be amended as necessary to carry out the intent of the parties pursuant to this Agreement. 

* * * * * 

  
 4 

			
	 

  
  
	  	 575 Florida St. Suite# 150

San Francisco, CA 94110, United States

+1-415-356-3400 | spire.com

  

 Please indicate your agreement with these terms by signing and dating this letter agreement
and returning them to me. These terms, if not accepted, will expire at the close of business in 7 days. 
 If you have any questions, please
call me at 415-356-3400. 
  

			
	Very truly yours,
	
	SPIRE GLOBAL, INC.
		
	By:	 	 Ananda Martin

		
	Signature:	 	 /s/ Ananda Martin

		
	Title:	 	 General Counsel

 I have read and accept this employment offer: 

 

			
	Peter Platzer	 	 /s/ Peter Platzer

	Signature of Employee
	
	 May 24, 2019

	Date

 Attachment 
 Exhibit A:
Foreign Assignment Letter 
 Exhibit B: Proprietary Information and Inventions Agreement 

  
 5 

			
	 

  
  
	  	 575 Florida St. Suite# 150

San Francisco, CA 94110, United States

+1-415-356-3400 | spire.com

  

 EXHIBIT A 

FOREIGN ASSIGNMENT LETTER 

  
 6 

 

 
  

 EXHIBIT B 

PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}]]